Phase 3 trial results support toripalimab plus chemotherapy as a first-line treatment option for patients with ES-SCLC, researchers say.

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Male sex was also shown to be an independent risk factor for longer hospital stays and increased hospitalization costs at ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Lung cancer is the top cause of cancer-related deaths globally, more prevalent in men, and ranks third among women. Both ...

Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative therapeutic ...

November is Lung Cancer Awareness Month, and early detection is in the air. According to the Centers for Disease Control, ...

Lung cancer is the leading cause of cancer deaths in America, and catching it early is vital. That’s exactly what a low-dose ...

Content by Intermountain Health Regional Communications. Did you know that raising awareness and encouraging screening can ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...

Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have ...

In a new study of patients with metastatic non-small cell lung cancer, researchers found that patients who were more physically fit had better outcomes. With lung cancer claiming around 1.8 million ...